BioMotiv is the mission-driven research accelerator associated with The Harrington Project for Discovery & Development, a $300 million initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.
Depixus is a young and dynamic biotechnology company based in Paris. Its goal is to commercialise a highly innovative technology platform for the fast, accurate, and inexpensive extraction of genetic and epigenetic information from single molecules of DNA and RNA. Originally developed in the Physics Department of École Normale Supérieure (ENS) in Paris, the potential of this exciting technology has been recognised through the award of numerous grants and innovation prizes at both national and international levels.
OptiKira is a start-up company developing novel therapeutics to prevent cell death. Founded in 2015, the company’s technology is based on discoveries developed and exclusively licensed from the University of California, San Francisco. Extensive research by the founders on the unfolded protein response has helped define the biological pathway leading to progressive cell death which characterises diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis.
Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology.
Verona Pharma plc is a UK-based clinical stage biotech company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.
Verona Pharma’s lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulised treatment for COPD patients with moderate to severe disease and possibly as a treatment of acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing and has received a Venture and Innovation Award from the Cystic Fibrosis Trust.
Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide.